Exploring autoantibody signatures in brain tissue from patients with severe mental illness.

Just D, Månberg A, Mitsios N, Stockmeier CA, Rajkowska G, Uhlén M, Mulder J, Feuk L, Cunningham JL, Nilsson P, Carlström EL

Transl Psychiatry 10 (1) 401 [2020-11-18; online 2020-11-18]

In recent years, studies have shown higher prevalence of autoantibodies in patients with schizophrenia compared to healthy individuals. This study applies an untargeted and a targeted affinity proteomics approach to explore and characterize the autoantibody repertoire in brain tissues from 73 subjects diagnosed with schizophrenia and 52 control subjects with no psychiatric or neurological disorders. Selected brain tissue lysates were first explored for IgG reactivity on planar microarrays composed of 11,520 protein fragments representing 10,820 unique proteins. Based on these results of ours and other previous studies of autoantibodies related to psychosis, we selected 226 fragments with an average length of 80 amino acids, representing 127 unique proteins. Tissue-based analysis of IgG reactivities using antigen suspension bead arrays was performed in a multiplex and parallel fashion for all 125 subjects. Among the detected autoantigens, higher IgG reactivity in subjects with schizophrenia, as compared to psychiatrically healthy subjects, was found against the glutamate ionotropic receptor NMDA type subunit 2D (anti-GluN2D). In a separate cohort with serum samples from 395 young adults with a wider spectrum of psychiatric disorders, higher levels of serum autoantibodies targeting GluN2D were found when compared to 102 control individuals. By further validating GluN2D and additional potential autoantigens, we will seek insights into how these are associated with severe mental illnesses.

Autoimmunity and Serology Profiling [Collaborative]

PubMed 33208725

DOI 10.1038/s41398-020-01079-8

Crossref 10.1038/s41398-020-01079-8

pii: 10.1038/s41398-020-01079-8
pmc: PMC7676257


Publications 7.2.7